List of patient-reported quality of life surveys

This page lists patient-reported quality of life surveys used in the field of medicine, pharmaceuticals, and other scientific trials. These surveys are patient-reported outcome measures, may be questionnaires or surveys, and may be used to evaluate patient satisfaction, symptoms, disease state, or psychological well-being.

List

  1. The Adult Asthma Quality of Life Questionnaire (AQLQ) was developed at McMaster University in Ontario, Canada and was published in 1992.[15] It has since been used as a comparison tool[16] as well as a tool in clinical trials.[17][18]
  2. The Asthma Life Impact Scale (ALIS) measure was developed in 2010 by Galen Research.[19] It has been translated into 16 languages.[20]
  1. The Parents’ Index of Quality of Life in Atopic Dermatitis (PiQOL-AD) measures the impact that atopic dermatitis has on quality of life, from the parents’ perspective.[21] It has 28 items and was developed simultaneously in the United Kingdom, The Netherlands, Germany, Italy, Spain, France and the United States.[22] It has been utilised in several research studies investigating the treatment of paediatric atopic dermatitis with pimecrolimus.[23][24][25] and also in a research study regarding health-related quality of life measurement in children in Ibero-American countries.[26]
  2. The Quality of Life Index for Atopic Dermatitis (QoLIAD) measures the impact that atopic dermatitis has on a given patient’s quality of life.[27] It is a 25 item questionnaire for patients over the age of 16.[28] The QoLIAD has also been utilized in studies looking into educational intervention,[29][30] topical corticosteroids[31] and pimecrolimus.[32]
  1. The Quality of Well-Being Scale (QWB) was developed in the 1970s, and a self-administered version called the QWB-SA was published in 1996.[59] The QWB has been used in studies investigating HIV patients[60][61] and musculoskeletal disease,[62] amongst others.
  2. The EQ-5D is a generalised health-related quality of life measure which was developed in 1991 by the EuroQol Group.[63] It has five standard dimensions and has been translated into over 60 languages.[64] The EuroQoL has been extensively used in clinical trials, investigating a range of topics including overactive bladder,[65] attention deficit hyperactivity disorder[66] and denosumab for osteoporosis.[67]
  3. The Nottingham Health Profile (NHP) is a general patient-reported outcome designed to measure a patient’s view of their own health status, in a number of areas.[68] It can be completed in 5 minutes.[69] It was developed in 1975 and current copyright belongs to Galen Research.[70] Clinical research studies where the NHP has been utilized include investigations into erythropoiesis-stimulating agents,[71] glucocorticoid replacement therapy[72] and transcutaneous electrical nerve stimulation for tinnitus.[73]
  4. The Short Form 36 (SF-36) Health Survey is a survey of general health developed by the RAND corporation.[74] It was designed for use in clinical practice, research, health policy evaluations and population surveys.[75] It has been used in numerous studies including ones investigating giardia intestinalis,[76] breast cancer survivors[77] and Parkinson's disease.[78]
  5. The Sickness Impact Profile (SIP) was developed in 1997 by the Johns Hopkins University.[79] It consists of 136 items and has been adapted for strokes,[80] patients with ileal urinary diversions[81] and ex-ICU patients.[82]
  6. The Health Utilities Index measures health status, health-related quality of life and produces utility scores.[83] It was developed by Health Utilities Inc. in Canada.[84] It has been used in clinical studies investigating knee osteoarthritis,[85] urinary incontinence[86] and children who have been admitted to intensive care.[87]
  1. The Herpes Outbreak Impact Questionnaire (HOIQ) is designed to determine the impact of recurrent genital herpes outbreaks on a patient’s life.[88] Its efficacy has been tested in an Australian clinical trial.[89]
  2. The Herpes Symptom Checklist (HSC) was developed alongside the HOIQ in order to assess daily symptoms of genital herpes outbreaks.[90] It was also used in an Australian clinical trial which tested the effectiveness of famciclovir.[91]
  3. The Recurrent genital herpes quality of life measure (RGHQoL) was developed in 1998 by Galen Research in order to assess the impact recurrent genital herpes has on quality of life.[92] It has been used in clinical trials investigating famciclovir,[93] suppressive antiviral therapy[94] and patient perspectives and quality of life.[95][96]

References

  1. "ACQLI" (PDF). Galen-Research.com. Galen Research. Retrieved 11 November 2013.
  2. Clinical trial number NCT00428090 for "Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease" at ClinicalTrials.gov
  3. Clinical trial number NCT00348309 for "Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy For Subjects With Mild To Moderate Alzheimer's Disease (REFLECT-2)" at ClinicalTrials.gov
  4. Clinical trial number NCT00348140 for "Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease (REFLECT-3)" at ClinicalTrials.gov
  5. Levy, Karen; Lanctôt, Krista L.; Farber, Shale B.; Li, Abby; Herrmann, Nathan (2012). "Does Pharmacological Treatment of Neuropsychiatric Symptoms in Alzheimerʼs Disease Relieve Caregiver Burden?". Drugs & Aging. 29 (3): 167–179. doi:10.2165/11599140-000000000-00000.
  6. Spertus, J.A.; Winder, J.A.; Dewhurst, T.A.; Deyo, R.A.; Prodzinski, J.; McDonell, M.; Fihn, S.D. (1995). "Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease". Journal of the American College of Cardiology. 25 (2): 333–341. doi:10.1016/0735-1097(94)00397-9. PMID 7829785. Retrieved 27 November 2013.
  7. Jitta, D.J.; DeJongste, M.J.; Kliphuis, C.M.; Staal, M.J. (2011). "Multimorbidity, the predominant predictor of quality-of-life, following successful spinal cord stimulation for angina pectoris.". Neuromodulation. 14 (1): 13–18. doi:10.1111/j.1525-1403.2010.00321.x. PMID 21992156.
  8. Villano, A; Di Franco, A.; Nerla, R.; Sestito, A.; Tarzia, P.; Lamendola, P.; Di Monaco, A.; Sarullo, F.M.; Lanza, G.A.; Crea, F. (2013). "Effects of ivabradine and ranolazine in patients with microvascular angina pectoris". The American Journal of Cardiology. 112 (1): 8–13. doi:10.1016/j.amjcard.2013.02.045. PMID 23558043.
  9. Andrelle, P.; Ekre, O.; Grip, L.; Wahrborg, P.; Albertsson, P.; Eliasson, T.; Jeppsson, A.; Mannheimer, C. (2011). "Fatality, morbidity and quality of life in patients with refractory angina pectoris.". International Journal of Cardiology. 147 (3): 377–382. doi:10.1016/j.ijcard.2009.09.538. PMID 19880202.
  10. Doward, L C; Spoorenberg, A; Cook, SA; Whalley, D; Helliwell, PS; Kay, LJ; McKenna, SP; Tennant, A; Van Der Heijde, D; Chamberlain, MA (2003). "Development of the ASQoL: A quality of life instrument specific to ankylosing spondylitis". Annals of the Rheumatic Diseases. 62 (1): 20–6. doi:10.1136/ard.62.1.20. PMC 1754293Freely accessible. PMID 12480664.
  11. Van Der Heijde, Désirée M; Revicki, Dennis A; Gooch, Katherine L; Wong, Robert L; Kupper, Hartmut; Harnam, Neesha; Thompson, Chris; Sieper, Joachim (2009). "Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis". Arthritis Research & Therapy. 11 (4): R124. doi:10.1186/ar2790.
  12. Davis, John C.; Revicki, Dennis; Van Der Heijde, Désirée M. F.; Rentz, Anne M.; Wong, Robert L.; Kupper, Hartmut; Luo, Michelle P. (2007). "Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: Results from a randomized controlled study". Arthritis & Rheumatism. 57 (6): 1050–1057. doi:10.1002/art.22887.
  13. Marzo-Ortega, Helena; McGonagle, Dennis; O'Connor, Philip; Emery, Paul (2001). "Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: A clinical and magnetic resonance imaging study". Arthritis & Rheumatism. 44 (9): 2112–2117. doi:10.1002/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-H.
  14. Marzo-Ortega, H; McGonagle, D; Haugeberg, G; Green, MJ; Stewart, SP; Emery, P (2003). "Bone mineral density improvement in spondyloarthropathy after treatment with etanercept". Annals of the Rheumatic Diseases. 62 (10): 1020–1. doi:10.1136/ard.62.10.1020. PMC 1754338Freely accessible. PMID 12972490.
  15. Juniper, E.F.; Guyatt, G.H.; Epstein, R.S.; Ferrie, P.J.; Jaeschke, R.; Hiller, T.K. (1992). "Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials". Thorax. 47 (2): 76–83. doi:10.1136/thx.47.2.76. PMC 463574Freely accessible. PMID 1549827. Retrieved 25 November 2013.
  16. Kim, M.A.; Ye, Y.M.; Park, J.W.; Lee, J.H.; Lee, S.K.; Kim, C.W.; Jung, K.S.; Kim, J.H.; Yoo, H.S.; Kim, S.H; Shin, Y.S; Nahm, D.H.; Park, H.S. (2013). "A Computerized Asthma-Specific Quality of Life: A Novel Tool for Reflecting Asthma Control and Predicting Exacerbation". International Archives of Allergy and Immunology. 163 (1): 36–42. doi:10.1159/000356336. PMID 24247849. Retrieved 25 November 2013.
  17. Cano Fuentes, G.; Dastis Bendala, C; Morales Barroso, I; Manzanares Torne, M.L.; Fernandez Gregorio, A.; Martin Romana, L.; Morales Barroso, I; Manzanares Torné, M. L.; Fernández Gregorio, A; Martín Romana, L (2013). "A randomised clinical trial to evaluate the effectiveness of an educational intervention developed for adult asthmatics in a primary care centre". Atencion primaria. 46 (3): 117–39. doi:10.1016/j.aprim.2013.04.005. PMID 24176681.
  18. Freitas, D.A.; Holloway, E.A.; Bruno, S.S.; Chaves, G.S.; Fregonezi, G.A.; Mendonca, K.M. (2013). "Breathing exercises for adults with asthma.". The Cochrane database of systematic reviews. 10 (10): CD001277. doi:10.1002/14651858.CD001277.pub3. PMID 24085551.
  19. Meads, David M.; McKenna, Stephen P.; Doward, Lynda C.; Pokrzywinski, Robin; Revicki, Dennis; Hunter, Cameron; Glendenning, G. Alastair (2010). "Development and validation of the Asthma Life Impact Scale (ALIS)". Respiratory Medicine. 104 (5): 633–43. doi:10.1016/j.rmed.2009.11.023. PMID 20053543.
  20. Crawford, SR. "Further Developments of the Asthma Life Impact Scale (ALIS)" (PDF). Galen-Research.com. Galen Research. Retrieved 14 October 2013.
  21. Arnold, RJG; Zhou, Y; Wong, KS; Sung, J (2005). "Psk8 Impact of Atopic Dermatitis on the Quality-Of-Life of Parents of Children with Atopic Dermatitis". Value in Health. 8 (3): 332. doi:10.1016/S1098-3015(10)62872-0.
  22. McKenna, Stephen P.; Whalley, Diane; Dewar, Abigail L.; Erdman, Ruud A. M.; Kohlmann, Thomas; Niero, Mauro; Baró, Eva; Cook, Sharon A.; Crickx, Beatrice; Frech, Feride; Van Assche, Daniel van (2005). "International development of the Parents' Index of Quality of Life in Atopic Dermatitis (PIQoL-AD)". Quality of Life Research. 14 (1): 231–41. doi:10.1007/s11136-004-4231-z. PMID 15789957.
  23. McKenna, SP; Whalley, D; De Prost, Y; Staab, D; Huels, J; Paul, CF; Van Assche, D (2006). "Treatment of paediatric atopic dermatitis with pimecrolimus (ElidelR, SDZ ASM 981): Impact on quality of life and health-related quality of life". Journal of the European Academy of Dermatology and Venereology. 20 (3): 248–54. doi:10.1111/j.1468-3083.2006.01383.x. PMID 16503881.
  24. Wahn, U.; Bos, J. D.; Goodfield, M.; Caputo, R.; Papp, K.; Manjra, A.; Dobozy, A.; Paul, C.; Molloy, S.; Hultsch, T.; Graeber, M.; Cherill, R.; De Prost, Y.; Flare Reduction in Eczema with Elidel (Children) Multicenter Investigator Study Group (2002). "Efficacy and Safety of Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Children". Pediatrics. 110 (1 Pt 1): e2. doi:10.1542/peds.110.1.e2. PMID 12093983.
  25. Kapp, Alexander; Papp, Kim; Bingham, Ann; Fölster-Holst, Regina; Ortonne, Jean-Paul; Potter, Paul C.; Gulliver, Wayne; Paul, Carle; Molloy, Stephen; Barbier, Nathalie; Thurston, Mark; De Prost, Yves; Flare Reduction in Eczema with Elidel (infants) multicenter investigator study group (2002). "Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug". Journal of Allergy and Clinical Immunology. 110 (2): 277–84. doi:10.1067/mai.2002.126500. PMID 12170269.
  26. Rajmil, Luis; Roizen, Mariana; Psy, Alfonso Urzúa; Hidalgo-Rasmussen, Carlos; Fernández, Gabriela; Dapueto, Juan José; Working Group on HRQOL in Children in Ibero-American Countries (2012). "Health-Related Quality of Life Measurement in Children and Adolescents in Ibero-American Countries, 2000 to 2010". Value in Health. 15 (2): 312–22. doi:10.1016/j.jval.2011.11.028. PMID 22433763.
  27. Meads, DM; McKenna, SP; Doward, LC; Hampson, N; McGeown, C (2005). "Psk6 Interpreting Scores on the Quality of Life Index for Atopic Dermatitis (Qoliad)". Value in Health. 8 (3): 331–332. doi:10.1016/S1098-3015(10)62870-7.
  28. Ehlken, B; Kugland, B; Schramm, B; Quednau, K; Berger, K (2003). "Psn12 Quality-Of-Life in Patients Suffering from Atopic Dermatitis in Germany". Value in Health. 6 (6): 787–788. doi:10.1016/S1098-3015(10)62005-0.
  29. Lambert, J.; Bostoen, J.; Geusens, B.; Bourgois, J.; Boone, J.; De Smedt, D.; Annemans, L. (2010). "A novel multidisciplinary educational programme for patients with chronic skin diseases: Ghent pilot project and first results". Archives of Dermatological Research. 303 (1): 57–63. doi:10.1007/s00403-010-1082-z. PMID 20842368.
  30. Bostoen, J.; Bracke, S.; De Keyser, S.; Lambert, J. (2012). "An educational programme for patients with psoriasis and atopic dermatitis: A prospective randomized controlled trial". British Journal of Dermatology. 167 (5): 1025–31. doi:10.1111/j.1365-2133.2012.11113.x. PMID 22709422.
  31. Moed, Heleen; Yang, Quan; Oranje, Arnold P; Panda, Saumya; Van Der Wouden, Johannes C (2012). Moed, Heleen, ed. "Cochrane Database of Systematic Reviews". Protocols. doi:10.1002/14651858.CD010080. |chapter= ignored (help)
  32. Lecomte, P; Lambert, J; Degreef, H; Lesaffre, E; De Backer, M (2006). "Psk6 Belgian Drug Utilisation Study of Elidel® in Routine Practice in Atopic Dermatitis". Value in Health. 9 (6): A268. doi:10.1016/S1098-3015(10)63408-0.
  33. Dawson, J; Fitzpatrick, R; Murray, D; Carr, A (1998). "Questionnaire on the perceptions of patients about total knee replacement". The Journal of bone and joint surgery. British volume. 80 (1): 63–9. doi:10.1302/0301-620X.80B1.7859. PMID 9460955.
  34. Xie, Feng; Ye, Hua; Zhang, Yu; Liu, Xia; Lei, Ting; Li, Shu-Chuen (2011). "Extension from inpatients to outpatients: Validity and reliability of the Oxford Knee Score in measuring health outcomes in patients with knee osteoarthritis". International Journal of Rheumatic Diseases. 14 (2): 206–10. doi:10.1111/j.1756-185X.2010.01580.x. PMID 21518321.
  35. McKenna, SP; Hunt, SM (1994). "A measure of family disruption for use in chickenpox and other childhood illnesses". Social science & medicine (1982). 38 (5): 725–31. doi:10.1016/0277-9536(94)90463-4. PMID 8171351.
  36. Mast, T Christopher; Demuro-Mercon, Carla; Kelly, Claudia M; Floyd, Leigh; Walter, Emmanuel B (2009). "The impact of rotavirus gastroenteritis on the family". BMC Pediatrics. 9: 11. doi:10.1186/1471-2431-9-11. PMC 2649068Freely accessible. PMID 19200366.
  37. Weldam, Saskia W.M.; Schuurmans, Marieke J.; Liu, Rani; Lammers, Jan-Willem J. (2013). "Evaluation of Quality of Life instruments for use in COPD care and research: A systematic review". International Journal of Nursing Studies. 50 (5): 688–707. doi:10.1016/j.ijnurstu.2012.07.017. PMID 22921317.
  38. "Measures Database". Galen-Research.com. Galen Research. Retrieved 11 October 2013.
  39. López-Campos, José Luis (2009). "Importancia de la fatiga, calidad del sueño y estado de ánimo en los pacientes con EPOC y la necesidad de disponer de instrumentos para su medición" [Importance of fatigue, sleep quality and mood in patients with chronic obstructive pulmonary disease and the need for measurement instruments]. Archivos de Bronconeumología (in Spanish). 45: 2–6. doi:10.1016/S0300-2896(09)72948-5. PMID 20116755.
  40. Amir, Marianne; Lewin-Epstein, Noah; Becker, Gideon; Buskila, Dan (2002). "Psychometric Properties of the SF-12 (Hebrew Version) in a Primary Care Population in Israel". Medical Care. 40 (10): 918–28. doi:10.1097/00005650-200210000-00009. PMID 12395025.
  41. McKenna, Stephen P.; Hunt, Sonja M. (1992). "A new measure of quality of life in depression: Testing the reliability and construct validity of the QLDS". Health Policy. 22 (3): 321–30. doi:10.1016/0168-8510(92)90005-V. PMID 10122731.
  42. Baca Baldomero, E; Cervera Enguix, S; Grupo De Estudio, Teseo (2003). "Quality of life, in depressed patients in Primary Health Care setting. Effectiveness and safety of venlafaxine extended release". Actas espanolas de psiquiatria. 31 (6): 331–8. PMID 14639509.
  43. Detke, Michael J.; Lu, Yili; Goldstein, David J.; McNamara, Robert K.; Demitrack, Mark A. (2002). "Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression". Journal of Psychiatric Research. 36 (6): 383–90. doi:10.1016/S0022-3956(02)00060-2. PMID 12393307.
  44. Hudson, James I; Perahia, David G; Gilaberte, Inmaculada; Wang, Fujun; Watkin, John G; Detke, Michael J (2007). "Duloxetine in the treatment of major depressive disorder: An open-label study". BMC Psychiatry. 7: 43. doi:10.1186/1471-244X-7-43. PMC 2018694Freely accessible. PMID 17725843.
  45. Kornstein, SG; Wohlreich, MM; Mallinckrodt, CH; Watkin, JG; Stewart, DE (2006). "Duloxetine efficacy for major depressive disorder in male vs. Female patients: Data from 7 randomized, double-blind, placebo-controlled trials". The Journal of Clinical Psychiatry. 67 (5): 761–70. doi:10.4088/JCP.v67n0510. PMID 16841626.
  46. Dunner, DL; Kwong, WJ; Houser, TL; Richard, NE; Donahue, RM; Khan, ZM (2001). "Improved Health-Related Quality of Life and Reduced Productivity Loss After Treatment with Bupropion Sustained Release: A Study in Patients with Major Depression". Primary care companion to the Journal of clinical psychiatry. 3 (1): 10–16. doi:10.4088/PCC.v03n0103. PMC 181153Freely accessible. PMID 15014623.
  47. Vickrey, B.G. (1993). "A procedure for developing a quality-of-life measure for epilepsy surgery patients.". Epilepsia. 34 (Suppl. 4): S22–S27. doi:10.1111/j.1528-1157.1993.tb05912.x. PMID 8348900.
  48. "Epilepsy Surgery Inventory 55 Survey (ESI-55)". RAND.org. RAND Health. Retrieved 27 November 2013.
  49. Selai, C.E.; Elstner, K; Trimble, M.R. (2000). "Quality of life pre and post epilepsy surgery". Epilepsy Research. 38 (1): 67–74. doi:10.1016/s0920-1211(99)00075-3. PMID 10604607. Retrieved 27 November 2013.
  50. de Conceicao, P.O.; Nascimento, P.P.; Mazetto, L.; Alonso, N.B.; Yacubian, E.M.; de Araujo Filho, G.M. (2013). "Are psychiatric disorders exclusion criteria for video-EEG monitoring and epilepsy surgery in patients with mesial temporal sclerosis?". Epilepsy & Behaviour. 27 (2): 310–314. doi:10.1016/j.yebeh.2013.02.014. Retrieved 27 November 2013.
  51. Monteiro Ede, A.; Osorio Fde, L.; Veriano, A Jr.; Molina, R.S.; Funayama, S.S.; Terra, V.C.; Velasco, T.R.;Guarnieri, R.; Bianchin, M.; Assirati, J.A. Jr.; Sakamoto, A.C.; Hallak, J.E. (2012). "Validation of the Subjective Handicap of Epilepsy (SHE) in Brazilian patients with epilepsy". Epilepsy & Behaviour. 24 (3): 345–351. doi:10.1016/j.yebeh.2012.04.129. Retrieved 27 November 2013.
  52. Mangione, Carol M.; Lee, Paul P.; Gutierrez, Peter R.; Spritzer, Karen; Berry, Sandra; Hays, Ron D. (2001). "Development of the 25-list-item National Eye Institute Visual Function Questionnaire". Archives of Ophthalmology. 119 (7): 1050–1058. doi:10.1001/archopht.119.7.1050. PMID 11448327. Retrieved 26 November 2013.
  53. Orr, Peggy; Rentz, Anne M.; Margolis, Mary Kay; Revicki, Dennis A.; Dolan, Chantal M.; Colman, Shoshana; Fine, Jennifer T.; Bressler, Neil M. (2011). "Validation of the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) in Age-Related Macular Degeneration". Investigative Ophthalmology and Visual Science. 52 (6): 3354–3359. doi:10.1167/iovs.10-5645. PMID 21282568. Retrieved 26 November 2013.
  54. Kirwan, Caitriona; Lanigan, Bernadette; O'Keefe, Michael (2012). "Vision-Related Quality of Life Assessment Using the NEI-VFQ-25 in Adolescents and Young Adults With a History of Congenital Cataract". Journal of Pediatric Ophthalmology and Strabismus. 49 (1): 26–31. doi:10.3928/01913913-20110517-02. PMID 21598855. Retrieved 26 November 2013.
  55. Naik, Rupali K.; Gries, Katharine S.; Rentz, Anne M.; Kowalski, Jonathan W.; Revicki, Dennis A. (2013). "Psychometric evaluation of the National Eye Institute Visual Function Questionnaire and Visual Function Questionnaire Utility Index in patients with non-infectious intermediate and posterior uveitis". Quality of Life Research. 22 (10): 2801–8. doi:10.1007/s11136-013-0412-y. PMID 23645458. Retrieved 26 November 2013.
  56. Meads, D.; Doward, L.; McKenna, S.; Fisk, J.; Twiss, J.; Eckert, B. (2009). "The development and validation of the Unidimensional Fatigue Impact Scale (U-FIS)". Multiple Sclerosis. 15 (10): 1228–38. doi:10.1177/1352458509106714. PMID 19556314.
  57. Elbers, Roy G.; Rietberg, Marc B.; Van Wegen, Erwin E. H.; Verhoef, John; Kramer, Sharon F.; Terwee, Caroline B.; Kwakkel, Gert (2011). "Self-report fatigue questionnaires in multiple sclerosis, Parkinson's disease and stroke: A systematic review of measurement properties". Quality of Life Research. 21 (6): 925–44. doi:10.1007/s11136-011-0009-2. PMC 3389599Freely accessible. PMID 22012025.
  58. "Measures Database". Galen-Research.com. Galen Research. Retrieved 20 November 2013.
  59. Kattan, Michael (2009). Encyclopedia of Medical Decision Making. SAGE Publications. ISBN 978-1-4129-7198-0.
  60. Kaplan, R. M.; Patterson, T. L.; Kerner, D. N.; Atkinson, J.; Heaton, R. K.; Grant, I. (1997). "The Quality of Well-Being scale in asymptomatic HIV-infected patients. HNRC Group. HIV Neural Behavioral Research Center". Quality of Life Research. 6 (6): 507–14. doi:10.1023/A:1018456031659. PMID 9330551.
  61. Hughes, T. E.; Kaplan, R. M.; Coons, S. J.; Draugalis, J. R.; Johnson, J. A.; Patterson, T. L. (1997). "Construct Validities of the Quality of Well-Being Scale and the MOS-HIV-34 Health Survey for HIV-infected Patients". Medical Decision Making. 17 (4): 439–46. doi:10.1177/0272989X9701700409. PMID 9343802.
  62. Frosch, Dominick L.; Kaplan, Robert M.; Ganiats, Theodore G.; Groessl, Erik J.; Sieber, William J.; Weisman, Michael H. (2004). "Validity of self-administered quality of well-being scale in musculoskeletal disease". Arthritis & Rheumatism. 51: 28–33. doi:10.1002/art.20071.
  63. Brooks, Richard (1996). "EuroQol: The current state of play". Health Policy. 37 (1): 53–72. doi:10.1016/0168-8510(96)00822-6. PMID 10158943.
  64. "Euroqol EQ-5D (EQ-5D)". PROQOLID.org. Mapi Research Trust. Retrieved 20 November 2013.
  65. Desroziers, K; Aballéa, S; Maman, K; Nazir, J; Odeyemi, I; Hakimi, Z (2013). "Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder". Health and quality of life outcomes. 11 (1): 200. doi:10.1186/1477-7525-11-200. PMID 24246044.
  66. Bouwmans, Clazien; Kolk, Annemarie; Oppe, Mark; Schawo, Saskia; Stolk, Elly; Agthoven, Michel; Buitelaar, Jan; Roijen, Leonahakkaart (2013). "Validity and responsiveness of the EQ-5D and the KIDSCREEN-10 in children with ADHD". The European Journal of Health Economics. 15 (9): 967–77. doi:10.1007/s10198-013-0540-x. PMID 24233919.
  67. Parthan, A.; Kruse, M.; Agodoa, I.; Silverman, S.; Orwoll, E. (2013). "Denosumab: A cost-effective alternative for older men with osteoporosis from a Swedish payer perspective". Bone. 59: 105–13. doi:10.1016/j.bone.2013.11.002. PMID 24231131.
  68. Hunt, Sonja M.; McKenna, S.P.; McEwen, J.; Williams, Jan; Papp, Evelyn (1981). "The Nottingham health profile: Subjective health status and medical consultations". Social Science & Medicine. Part A: Medical Psychology & Medical Sociology. 15 (3): 221–9. doi:10.1016/0271-7123(81)90005-5. PMID 6973203.
  69. Ebrahim, S; Barer, D; Nouri, F (1986). "Use of the Nottingham Health Profile with patients after a stroke". Journal of Epidemiology & Community Health. 40 (2): 166–9. doi:10.1136/jech.40.2.166. PMC 1052513Freely accessible. PMID 3746178.
  70. Hunt, SM; McEwen, J; McKenna, SP (1985). "Measuring health status: A new tool for clinicians and epidemiologists". The Journal of the Royal College of General Practitioners. 35 (273): 185–8. PMC 1960139Freely accessible. PMID 3989783.
  71. Johansen, K. L.; Finkelstein, F. O.; Revicki, D. A.; Evans, C.; Wan, S.; Gitlin, M.; Agodoa, I. L. (2011). "Systematic review of the impact of erythropoiesis-stimulating agents on fatigue in dialysis patients". Nephrology Dialysis Transplantation. 27 (6): 2418–25. doi:10.1093/ndt/gfr697. PMID 22187314.
  72. Behan, Lucy-Ann; Rogers, Bairbre; Hannon, Mark J.; O'Kelly, Patrick; Tormey, William; Smith, Diarmuid; Thompson, Christopher J.; Agha, Amar (2011). "Optimizing glucocorticoid replacement therapy in severely adrenocorticotropin-deficient hypopituitary male patients". Clinical Endocrinology. 75 (4): 505–13. doi:10.1111/j.1365-2265.2011.04074.x. PMID 21521342.
  73. Aydemir, G; Tezer, M S; Borman, P; Bodur, H; Unal, A (2006). "Treatment of tinnitus with transcutaneous electrical nerve stimulation improves patients' quality of life". The Journal of Laryngology & Otology. 120 (6): 442–5. doi:10.1017/S0022215106000910. PMID 16556347.
  74. "36-Item Short Form Survey from the RAND Medical Outcomes Study". RAND.org. RAND. Retrieved 20 November 2013.
  75. Ware, John E.; Sherbourne, Cathy Donald (1992). "The MOS 36-ltem Short-Form Health Survey (SF-36)". Medical Care. 30 (6): 473–83. doi:10.1097/00005650-199206000-00002. PMID 1593914.
  76. Abulhasan, Mohamad; Elshazly, Tarek A.; Eida, Mohamad; Albadry, Ayman (2013). "Giardia intestinalis in patients with nonulcer dyspepsia". Arab Journal of Gastroenterology. 14 (3): 126–9. doi:10.1016/j.ajg.2013.08.004. PMID 24206742.
  77. Cuevas, BT; Hughes, DC; Parma, DL; Treviño-Whitaker, RA; Ghosh, S; Li, R; Ramirez, AG (2013). "Motivation, exercise, and stress in breast cancer survivors". Supportive Care in Cancer. 22 (4): 911–7. doi:10.1007/s00520-013-2038-6. PMC 3943705Freely accessible. PMID 24249424.
  78. Avidan, Alon; Hays, Ron D.; Diaz, Natalie; Bordelon, Yvette; Thompson, Alexander W.; Vassar, Stefanie D.; Vickrey, Barbara G. (2013). "Associations of Sleep Disturbance Symptoms with Health-Related Quality of Life in Parkinson's Disease". Journal of Neuropsychiatry. 25 (4): 319–326. doi:10.1176/appi.neuropsych.12070175.
  79. Gilson, BS; Gilson, JS; Bergner, M; Bobbit, RA; Kressel, S; Pollard, WE; Vesselago, M (1975). "The sickness impact profile. Development of an outcome measure of health care". American Journal of Public Health. 65 (12): 1304–10. doi:10.2105/AJPH.65.12.1304. PMC 1776251Freely accessible. PMID 1200192.
  80. Van Straten, A.; De Haan, R. J.; Limburg, M.; Schuling, J.; Bossuyt, P. M.; Van Den Bos, G. A. M. (1997). "A Stroke-Adapted 30-Item Version of the Sickness Impact Profile to Assess Quality of Life (SA-SIP30)". Stroke. 28 (11): 2155–61. doi:10.1161/01.STR.28.11.2155. PMID 9368557.
  81. Prcic, Alden; Aganovic, Damir; Hadziosmanovic, Osman (2013). "Sickness Impact Profile (SIP) Score, a Good Alternative Instrument for Measuring Quality of Life in Patients with Ileal Urinary Diversions". Acta Informatica Medica. 21 (3): 160–5. doi:10.5455/aim.2013.21.160-165. PMC 3804474Freely accessible. PMID 24167383.
  82. Hulsebos, R. G.; Beltman, F. W.; Dos Reis Miranda, D.; Spangenberg, J. F. A. (1991). "Measuring quality of life with the sickness impact profile: A pilot study". Intensive Care Medicine. 17 (5): 285–8. doi:10.1007/BF01713939. PMID 1939874.
  83. Horsman, John; Furlong, William; Feeny, David; Torrance, George (2003). "The Health Utilities Index (HUI): Concepts, measurement properties and applications". Health and Quality of Life Outcomes. 1: 54. doi:10.1186/1477-7525-1-54. PMC 293474Freely accessible. PMID 14613568.
  84. Furlong, WJ; Feeny, DH; Torrance, GW; Barr, RD (2001). "The Health Utilities Index (HUI) system for assessing health-related quality of life in clinical studies". Annals of Medicine. 33 (5): 375–84. doi:10.3109/07853890109002092. PMID 11491197.
  85. Davis, E. M.; Lynd, L. D.; Grubisic, M.; Kopec, J. A.; Sayre, E. C.; Cibere, J.; Esdaile, J.; Marra, C. A. (2013). "Responsiveness of Health State Utility Values in Knee Osteoarthritis". The Journal of Rheumatology. 40 (12): 2075–82. doi:10.3899/jrheum.130176. PMID 24187098.
  86. Harvie, Heidi S.; Shea, Judy A.; Andy, Uduak U.; Propert, Kate; Schwartz, J. Sanford; Arya, Lily A. (2013). "Validity of utility measures for women with urge, stress, and mixed urinary incontinence". American Journal of Obstetrics and Gynecology. 210: 85.e1. doi:10.1016/j.ajog.2013.09.025.
  87. Ebrahim, S.; Parshuram, C. (2013). "Comparison of utility scores from the Visual Analog Scale and Health Utilities Index 3 in children following pediatric intensive care unit admission". Journal of Child Health Care. 19: 53–62. doi:10.1177/1367493513496909.
  88. Doward, LC; McKenna, SP; Meads, DM (2003). "Pin41 Development of the Herpes Outbreak Impact Questionnaire (Hoiq)". Value in Health. 6 (6): 760–761. doi:10.1016/S1098-3015(10)61938-9.
  89. Meads, David M.; McKenna, Stephen P.; Bonney, Mary-Ann; Bloch, Mark T. (2009). "Further Validation and Responsiveness Assessment of the Herpes Outbreak Impact Questionnaire and Herpes Symptom Checklist". Value in Health. 12 (2): 397–400. doi:10.1111/j.1524-4733.2008.00450.x. PMID 18783390.
  90. Doward, Lynda C.; McKenna, Stephen P.; Meads, David M.; Kahler, Kristijan; Frech, Feride (2009). "The Development of the Herpes Symptom Checklist and the Herpes Outbreak Impact Questionnaire". Value in Health. 12 (1): 139–45. doi:10.1111/j.1524-4733.2008.00424.x. PMID 18647252.
  91. Twiss, J.; McKenna, S.; Bloch, M.; Bonney, M.A. (2011). "PIN5 Patient and Clinician Perceived Benefit of Early Consumption of Famciclovir for the Treatment of Herpes Outbreaks". Value in Health. 14 (7): A266. doi:10.1016/j.jval.2011.08.193.
  92. Doward, L. C; McKenna, S. P; Kohlmann, T; Niero, M; Patrick, D; Spencer, B; Thorsen, H. (1998). "The international development of the RGHQoL: A quality of life measure for recurrent genital herpes". Quality of Life Research. 7 (2): 143–53. doi:10.1023/A:1008857426633. PMID 9523496.
  93. Bartlett, Brenda L.; Tyring, Stephen K.; Fife, Kenneth; Gnann Jr, John W.; Hadala, Joseph T.; Kianifard, Farid; Berber, Erhan (2008). "Famciclovir treatment options for patients with frequent outbreaks of recurrent genital herpes: The RELIEF trial". Journal of Clinical Virology. 43 (2): 190–5. doi:10.1016/j.jcv.2008.06.004. PMID 18621575.
  94. Patel, R; Tyring, S; Strand, A; Price, MJ; Grant, DM (1999). "Impact of suppressive antiviral therapy on the health related quality of life of patients with recurrent genital herpes infection". Sexually transmitted infections. 75 (6): 398–402. doi:10.1136/sti.75.6.398. PMC 1758256Freely accessible. PMID 10754944.
  95. Spencer, B; Leplège, A; Ecosse, E (1999). "Recurrent genital herpes and quality of life in France". Quality of life research. 8 (4): 365–71. doi:10.1023/A:1008904227182. PMID 10472169.
  96. Patel, R; Boselli, F; Cairo, I; Barnett, G; Price, M; Wulf, HC (2001). "Patients' perspectives on the burden of recurrent genital herpes". International journal of STD & AIDS. 12 (10): 640–5. doi:10.1258/0956462011923859. PMID 11564330.
  97. 1 2 Wirén, L.; Whalley, D; McKenna, S; Wilhelmsen, L (2000). "Application of a disease-specific, quality-of-life measure (QoL-AGHDA) in growth hormone-deficient adults and a random population sample in Sweden: Validation of the measure by Rasch analysis". Clinical Endocrinology. 52 (2): 143–52. doi:10.1046/j.1365-2265.2000.00899.x. PMID 10671940.
  98. Moock, Joern; Friedrich, Nele; Völzke, Henry; Spielhagen, Christin; Nauck, Matthias; Koltowska-Häggström, Maria; Buchfelder, Michael; Wallaschofski, Henri; Kohlmann, Thomas (2011). "Prediction of improvement in quality of life (QoL-AGHDA) in adults with growth hormone deficiency by normative reference limits: Data of the German KIMS cohort". Growth Hormone & IGF Research. 21 (5): 272–8. doi:10.1016/j.ghir.2011.07.005. PMID 21865066.
  99. Gilet, Hélène; Chachuat, Anne; Viala-Danten, Muriel; Auzière, Sébastien; Koltowska-Häggström, Maria (2010). "Application of the Disease-Specific Quality of Life Assessment of Growth Hormone Deficiency in Adults (QoL-AGHDA) Questionnaire in a General Population: Results from a French Panel Study". Value in Health. 13 (4): 495–500. doi:10.1111/j.1524-4733.2009.00689.x. PMID 20102556.
  100. Badia, X.; Lucas, A.; Sanmartí, A.; Roset, M.; Ulied, A. (1998). "One-year follow-up of quality of life in adults with untreated growth hormone deficiency". Clinical Endocrinology. 49 (6): 765–71. doi:10.1046/j.1365-2265.1998.00634.x. PMID 10209564.
  101. Mukherjee, A.; Tolhurst-Cleaver, S.; Ryder, W. D. J.; Smethurst, L.; Shalet, S. M. (2004). "The Characteristics of Quality of Life Impairment in Adult Growth Hormone (GH)-Deficient Survivors of Cancer and Their Response to GH Replacement Therapy". Journal of Clinical Endocrinology & Metabolism. 90 (3): 1542–9. doi:10.1210/jc.2004-0832. PMID 15613427.
  102. Gutiérrez, Lia P.; Kołtowska-Häggström, Maria; Jönsson, Peter J.; Mattsson, Anders F.; Svensson, Dag; Westberg, Björn; Luger, Anton (2008). "Registries as a tool in evidence-based medicine: Example of KIMS (Pfizer International Metabolic Database)". Pharmacoepidemiology and Drug Safety. 17 (1): 90–102. doi:10.1002/pds.1510. PMID 17957812.
  103. Hays, R.D.; Kallich, J.D.; Mapes, D.L.; Coons, S.J.; Carter, W.B. (1994). "Development of the Kidney Disease Quality of Life (KDQOLTM) Instrument". Quality of Life Research. 3 (5): 329–338. doi:10.1007/BF00451725. PMID 7841967. Retrieved 25 November 2013.
  104. Fan, W.F.; Zhang, Q.; Luo, L.H.; Niu, J.Y.; Gu, Y. (2013). "Study on the Clinical Significance and Related Factors of Thirst and Xerostomia in Maintenance Hemodialysis Patients". Kidney and Blood Pressure Research. 37 (4–5): 464–474. doi:10.1159/000355717. PMID 24247643. Retrieved 25 November 2013.
  105. Cortes-Sanabria, Laura; Paredes-Cesena, Carlos A.; Herrera-Llamas, Rebeca M.; Cruz-Bueno, Yolanda; Soto-Molina, Herman; Pazarin, Leonardo; Cortes, Margarita; Martinez-Ramirez, Hector R. (2013). "Comparison of Cost-Utility Between Automated Peritoneal Dialysis and Continuous Ambulatory Peritoneal Dialysis". Archives of Medical Research. 44 (8): 655–61. doi:10.1016/j.arcmed.2013.10.017. PMID 24211750.
  106. Fidan, F.; Alkan, B.M.; Tosun, A.; Altunoglu, A; Ardicoglu, O. (2013). "Quality of life and correlation with musculoskeletal problems, hand disability and depression in patients with hemodialysis". International Journal of Rheumatic Disease: n/a. doi:10.1111/1756-185X.12171.
  107. Patrick, Donald L.; Hurst, Bryan C.; Hughes, Janette (2000). "Further Development and Testing of the Migraine-Specific Quality of Life (MSQOL) Measure". Headache: the Journal of Head and Face Pain. 40 (7): 550–560. doi:10.1046/j.1526-4610.2000.00086.x.
  108. Garcia-Monco, JC; Foncea, N; Bilbao, A; Ruiz De Velasco, I; Gomez-Beldarrain, M (2007). "Impact of preventive therapy with nadolol and topiramate on the quality of life of migraine patients". Cephalalgia. 27 (8): 920–8. doi:10.1111/j.1468-2982.2007.01367.x. PMID 17645757.
  109. Spigt, M.; Weerkamp, N.; Troost, J.; Van Schayck, C. P.; Knottnerus, J. A. (2011). "A randomized trial on the effects of regular water intake in patients with recurrent headaches". Family Practice. 29 (4): 370–5. doi:10.1093/fampra/cmr112. PMID 22113647.
  110. Mérelle, SY; Sorbi, MJ; Van Doornen, LJ; Passchier, J (2008). "Migraine patients as trainers of their fellow patients in non-pharmacological preventive attack management: Short-term effects of a randomized controlled trial". Cephalalgia. 28 (2): 127–38. doi:10.1111/j.1468-2982.2007.01472.x (inactive 2015-01-14). PMID 18197883.
  111. Doward, L.; McKenna, S.; Meads, D.; Twiss, J; Eckert, B. (2009). "The development of patient-reported outcome indices for multiple sclerosis (PRIMUS)". Multiple Sclerosis. 15 (9): 1092–102. doi:10.1177/1352458509106513. PMID 19556315.
  112. "Poster I". Multiple Sclerosis Journal. 18 (4 Suppl): 55–277. 2012. doi:10.1177/1352458512459019.
  113. van Lokven, T.; Kempcke, R.; Ziemssen, T.; Meergans, M. (October 20, 2011). "Study design of a non-interventional registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients (PANGAEA)". 5th Joint triennial congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis. Amsterdam, The Netherlands. Retrieved October 9, 2013.
  114. Cascione, Mark; Wynn, Daniel; Agashivala, Neetu; McCague, Kevin; Pestreich, Linda; Schofield, Lesley; Kim, Edward; Barbato, Luigi (12 February 2013). "Patient-Reported Treatment Satisfaction, Reasons for Therapy Change, and Health-Related Quality of Life at Baseline from the Trial To Evaluate Patient OutComes, Safety and Tolerability of Fingolimod". Neurology. 80 (1). Retrieved 9 October 2013.
  115. Maurer, M.; Ortler, S.; Baier, M.; Meergans, M.; Scherer, P.; Hofmann, W.; Tracik, F. (2012). "Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients". Multiple Sclerosis Journal. 19 (5): 631–8. doi:10.1177/1352458512463481. PMID 23069874.
  116. Keenan, Anne-Maree; McKenna, Stephen P.; Doward, Lynda C.; Conaghan, Philip G.; Emery, Paul; Tennant, Alan (2008). "Development and validation of a needs-based quality of life instrument for osteoarthritis". Arthritis & Rheumatism. 59 (6): 841–848. doi:10.1002/art.23714.
  117. "Treating painful hand osteoarthritis using low dose oral prednisolone- assessing short-term pain and imaging outcomes". EU Clinical Trials Register. European Medicines Agency. Retrieved 20 November 2013.
  118. "An open label study to assess the effectiveness of oral methotrexate in reducing pain in knee osteoarthritis". EU Clinical Trials Register. European Medicines Agency. Retrieved 20 November 2013.
  119. "HERO:Hydroxychloroquine Effectiveness in Reducing Symptoms of hand OA, a randomised, double-blind, placebo-controlled trial". Eu Clinical Trials Register. European Medicines Council. Retrieved 20 November 2013.
  120. Abbas, M.; Schwartz, M.; Smith, F.J.D.; McLean, W.H.I.; Hull, P. (2014). "PCQoL: A Quality of Life Assessment Measure for Pachyonychia Congenita". Journal of Cutaneous Medicine and Surgery. 19: 57–65. doi:10.2310/7750.2014.14017. PMID 25775665.
  121. 1 2 De Jong, Z.; Van Der Heijde, D.; McKenna, S. P.; Whalley, D. (1997). "The reliability and construct validity of the RAQoL: A rheumatoid arthritis-specific quality of life instrument". Rheumatology. 36 (8): 878–883. doi:10.1093/rheumatology/36.8.878.
  122. Adams, J.; Chapman, J.; Bradley, S.; Ryan, S. J. (2012). "Literacy levels required to complete routinely used patient-reported outcome measures in rheumatology". Rheumatology. 52 (3): 460–4. doi:10.1093/rheumatology/kes296. PMID 23118412.
  123. Dougados, M.; Kissel, K.; Sheeran, T.; Tak, P. P.; Conaghan, P. G.; Mola, E. M.; Schett, G.; Amital, H.; Navarro-Sarabia, F.; Hou, A.; Bernasconi, C.; Huizinga, T. (2012). "Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)". Annals of the Rheumatic Diseases. 72 (1): 43–50. doi:10.1136/annrheumdis-2011-201282. PMC 3551223Freely accessible. PMID 22562983.
  124. "Efficacy of tocilizumab in patients with rheumatoid arthritis". Current Controlled Trials. Springer Science+Business Media. Retrieved 2 October 2013.
  125. Quinn, Mark A.; Conaghan, Philip G.; O'Connor, Philip J.; Karim, Zunaid; Greenstein, Adam; Brown, Andrew; Brown, Clare; Fraser, Alexander; Jarret, Stephen; Emery, Paul (2005). "Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month randomized, double-blind, placebo-controlled trial". Arthritis & Rheumatism. 52: 27–35. doi:10.1002/art.20712.
  126. Bejarano, V.; Conaghan, P. G.; Quinn, M. A.; Saleem, B.; Emery, P. (2010). "Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis". Rheumatology. 49 (10): 1971–4. doi:10.1093/rheumatology/keq194. PMID 20595536.
  127. McKenna, Stephen P; Ratcliffe, Julie; Meads, David M; Brazier, John E (2008). "Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses". Health and Quality of Life Outcomes. 6: 65. doi:10.1186/1477-7525-6-65. PMC 2546377Freely accessible. PMID 18718016.
  128. McKenna, S. P.; Doughty, N.; Meads, D. M.; Doward, L. C.; Pepke-Zaba, J. (2006). "The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): A Measure of Health-Related Quality of Life and Quality of Life for Patients with Pulmonary Hypertension". Quality of Life Research. 15 (1): 103–15. doi:10.1007/s11136-005-3513-4. PMID 16411035.
  129. "Measures Database". Galen-Research.com. Galen Research. Retrieved 2 October 2013.
  130. Channick, Richard; Voswinckel; Rubin, Lewis; Vultaggio (2012). "Inhaled treprostinil: A therapeutic review". Drug Design, Development and Therapy. 6: 19–28. doi:10.2147/DDDT.S19281. PMC 3267519Freely accessible. PMID 22291467.
  131. Chen, Hubert; Rosenzweig, Erika B; Gotzkowsky, S Karl; Arneson, Carl; Nelsen, Andrew C; Bourge, Robert C (2013). "Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension". Health and Quality of Life Outcomes. 11: 31. doi:10.1186/1477-7525-11-31. PMC 3610124Freely accessible. PMID 23496856.
  132. Tay, Edgar L.W.; Papaphylactou, Maria; Diller, Gerhard Paul; Alonso-Gonzalez, Rafael; Inuzuka, Ryo; Giannakoulas, Georgios; Harries, Carl; Wort, Stephen John; Swan, Lorna; Dimopoulos, Konstantinos; Gatzoulis, Michael A. (2011). "Quality of life and functional capacity can be improved in patients with Eisenmenger syndrome with oral sildenafil therapy". International Journal of Cardiology. 149 (3): 372–6. doi:10.1016/j.ijcard.2010.02.020. PMID 20304507.
  133. Suntharalingam, Jay; Treacy, C. M.; Doughty, N. J.; Goldsmith, K; Soon, E; Toshner, M. R.; Sheares, K. K.; Hughes, R; Morrell, N. W.; Pepke-Zaba, J (2008). "Long-term Use of Sildenafil in Inoperable Chronic Thromboembolic Pulmonary Hypertension". CHEST Journal. 134 (2): 229–36. doi:10.1378/chest.07-2681. PMID 18263674.
  134. McKenna, Stephen P.; Lebwohl, Mark; Kahler, Kristijan N. (2005). "Development of the US PSORIQoL: A psoriasis-specific measure of quality of life". International Journal of Dermatology. 44 (6): 462–9. doi:10.1111/j.1365-4632.2005.01941.x. PMID 15941432.
  135. McKenna, S.P.; Cook, S.A.; Whalley, D.; Doward, L.C.; Richards, H.L.; Griffiths, C.E.M.; Van Assche, D. (2003). "Development of the PSORIQoL, a psoriasis-specific measure of quality of life designed for use in clinical practice and trials". British Journal of Dermatology. 149 (2): 323–31. doi:10.1046/j.1365-2133.2003.05492.x. PMID 12932239.
  136. "Measures Database". Galen-Research.com. Galen Research. Retrieved 13 November 2013.
  137. "Psoriasis: management of psoriasis" (PDF). NICE.org.uk. National Institute for Health and Care Excellence. Retrieved 13 November 2013.
  138. "CAEB071C2201". ClinicalTrialsRegister.eu. EU Clinical Trials Register. Retrieved 13 November 2013.
  139. Brodszky, V; Péntek, M; Bálint, PV; Géher, P; Hajdu, O; Hodinka, L; Horváth, G; Koó, É; Polgár, A; Seszták, M; Szántó, S; Ujfalussy, I; Gulácsi, L (2010). "Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: Results from a cross-sectional survey". Scandinavian Journal of Rheumatology. 39 (4): 303–9. doi:10.3109/03009740903468982. PMID 20166848.
  140. McKenna, S P; Doward, LC; Whalley, D; Tennant, A; Emery, P; Veale, DJ (2004). "Development of the PsAQoL: A quality of life instrument specific to psoriatic arthritis". Annals of the Rheumatic Diseases. 63 (2): 162–9. doi:10.1136/ard.2003.006296. PMC 1754880Freely accessible. PMID 14722205.
  141. Marzo-Ortega, H.; McGonagle, D.; Rhodes, L. A; Tan, A.; Conaghan, P. G; O'Connor, P.; Tanner, S. F; Fraser, A.; Veale, D.; Emery, P. (2007). "Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis". Annals of the Rheumatic Diseases. 66 (6): 778–81. doi:10.1136/ard.2006.063818. PMC 1954680Freely accessible. PMID 17185324.
  142. Clinical trial number NCT00427362 for "A Canadian Open-Label Study to Evaluate the Safety and Effectiveness of Adalimumab When Added to Inadequate Therapy for the Treatment of Psoriatic Arthritis (PsA) (ACCLAIM)" at ClinicalTrials.gov
  143. Brown, Benjamin C.; McKenna, Stephen P.; Solomon, Mattea; Wilburn, Jeanette; McGrouther, Duncan A.; Bayat, Ardeshir (2010). "The Patient-Reported Impact of Scars Measure: Development and Validation". Plastic and Reconstructive Surgery. 125 (5): 1439–49. doi:10.1097/PRS.0b013e3181d4fd89. PMID 20440163.
  144. Wilburn, J; McKenna, SP; Brown, B; Solomon, M; McGrouther, DA; Bayat, A (2009). "Pss36 Development and Validation of the Patient-Reported Impact of Scars Measure (Prism)". Value in Health. 12 (7): A459. doi:10.1016/S1098-3015(10)75273-6.
  145. Doward, L C; McKenna, S P; Whalley, D; Tennant, A; Griffiths, B; Emery, P; Veale, D J (2009). "The development of the L-QoL: A quality-of-life instrument specific to systemic lupus erythematosus". Annals of the Rheumatic Diseases. 68 (2): 196–200. doi:10.1136/ard.2007.086009. PMID 18385276.
  146. Castelino, M.; Abbott, J.; McElhone, K.; Teh, L.-S. (2012). "Comparison of the psychometric properties of health-related quality of life measures used in adults with systemic lupus erythematosus: A review of the literature". Rheumatology. 52 (4): 684–96. doi:10.1093/rheumatology/kes370. PMID 23264550.
  147. Yazdany, Jinoos (2011). "Health-related quality of life measurement in adult systemic lupus erythematosus: Lupus Quality of Life (LupusQoL), Systemic Lupus Erythematosus-Specific Quality of Life Questionnaire (SLEQOL), and Systemic Lupus Erythematosus Quality of Life Questionnaire". Arthritis Care & Research. 63: S413. doi:10.1002/acr.20636.
This article is issued from Wikipedia - version of the 11/8/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.